463 related articles for article (PubMed ID: 6500759)
1. Differences in steady-state plasma levels between aminophylline and theophylline sustained-release micropellets after repeated circadian dosing.
Schulz HU; Steinijans VW; Gabel H
Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):621-5. PubMed ID: 6500759
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Schuppan D; Molz KH; Staib AH; Rietbrock N
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
[TBL] [Abstract][Full Text] [Related]
3. Comparison of steady state serum theophylline concentrations in healthy volunteers after dosing with Euphyllin retard and PulmiDur.
Karlsson S; Lührmann B; Bahner ML; Schulz HU
Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):342-6. PubMed ID: 3623739
[TBL] [Abstract][Full Text] [Related]
4. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
Steinijans VW; Zech K; Fischer R
Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
[TBL] [Abstract][Full Text] [Related]
5. Absorption of sustained-release theophylline tablets.
Fagerström PO; Heintz L
Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
[TBL] [Abstract][Full Text] [Related]
6. [Bioavailability of a delayed-action aminophylline preparation].
Regazzi MB; Guarnone E; Bartoli A; Ciardelli L; Piacentini P
Minerva Med; 1985 Mar; 76(13):641-5. PubMed ID: 3991030
[TBL] [Abstract][Full Text] [Related]
7. The influence of enteral feedings on sustained-release theophylline absorption.
Plezia PM; Thornley SM; Kramer TH; Armstrong EP
Pharmacotherapy; 1990; 10(5):356-61. PubMed ID: 2122422
[TBL] [Abstract][Full Text] [Related]
8. Influence of morning or evening administration on absorption of theophylline.
Su YM; Cheng TP; Yeh TW; Wen CY; Wang DI
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):113-8. PubMed ID: 10677921
[TBL] [Abstract][Full Text] [Related]
9. The design of oral sustained-release theophylline dosing after conversion from intravenous to oral therapy.
Yamazaki M; Fukutomi O; Kondo N; Kato Z; Nakashima Y; Shinoda S; Agata H; Kondo T; Imaeda N; Orii T
Int J Clin Pharmacol Ther; 1994 Nov; 32(11):625-31. PubMed ID: 7874380
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of sustained release and conventional tablets of theophylline plus hydroxyethyltheophylline and its comparison with tablet aminophylline.
Gupta S; Raina RK; Samotra K; Gupta KL
Indian J Chest Dis Allied Sci; 1991; 33(1):1-8. PubMed ID: 1791015
[TBL] [Abstract][Full Text] [Related]
11. Absorption of theophylline from conventional and sustained-release tablets.
Fagerström PO; Mellstrand T; Svedmyr N
Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
[TBL] [Abstract][Full Text] [Related]
12. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y
Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of three sustained-release theophylline preparations (350 mg Theograd, 350 mg Theolair Retard and 300 mg Theodur) in steady state in healthy volunteers and asthmatics--Part I: Theophylline plasma levels.
van der Vet AP; Drost RH; Kreukniet J; Maes RA
Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):423-9. PubMed ID: 6490224
[TBL] [Abstract][Full Text] [Related]
14. Comparative bio-availability of theophylline whole and halved sustained-release tablets.
Müller FO; Hundt HK; Luus HG; van Dyk M; Groenewoud G; van der Meer MJ; Steinijans VW
S Afr Med J; 1987 Aug; 72(3):175-8. PubMed ID: 3299763
[TBL] [Abstract][Full Text] [Related]
15. Absorption of theophylline from conventional and sustained-release tablets.
Mellstrand T; Svedmyr N; Fagerström PO
Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of sustained-release theophylline formulations.
Bonora Regazzi M; Rondanelli R; Vidale E; Cristiani D
Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):245-51. PubMed ID: 6862729
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
[TBL] [Abstract][Full Text] [Related]
18. [Bioavailability of theophylline after oral administration of a retard preparation of theophylline-ethylenediamine and the influence of 15-day ingestion on elimination kinetics after i.v. injection (author's transl)].
Wiessmann KJ
Arzneimittelforschung; 1980; 30(2):329-32. PubMed ID: 7378114
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis.
Valet SB; Schwartz RH; Brooks JG
Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982
[TBL] [Abstract][Full Text] [Related]
20. The relation of product formulation to absorption of oral theophylline.
Weinberger M; Hendeles L; Bighley L
N Engl J Med; 1978 Oct; 299(16):852-7. PubMed ID: 692577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
